Literature DB >> 27491972

Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population.

Yunjia Tang1, Wenhua Yan1, Ling Sun1, Jie Huang1, Weiguo Qian1, Yueyue Ding1, Haitao Lv2.   

Abstract

The objectives of the study were to find the risk factors associated with intravenous immunoglobulin (IVIG) resistance and generate a prediction scoring system of IVIG resistance in patients with Kawasaki disease (KD). We retrospectively reviewed the clinical records of KD patients between January 2006 and December 2014. Multivariate logistic regression was performed to identify the risk factors of IVIG non-responders. The independent risk factors were used to construct a new scoring system and compared with Kobayashi and Egami scoring systems. Multivariate logistic regression analysis identified age <6 months, rash, edema of extremities, % neutrophils, and serum albumin as independent risk factors for IVIG non-responders. We assigned one point for rash, edema of extremities, and % neutrophils ≥80 %. Two points were assigned for age <6 months and serum albumin <35 g/L. Using a cutoff point of three or more, we identified the IVIG non-responders with 71.4 % sensitivity and 76.0 % specificity. The new scoring system had a relatively better performance than Kobayashi and Egami scoring systems in the KD patients in East China. Clinical pediatricians must pay more attention to these high-risk patients, and use of additional therapies early in the course of their illness is necessary.

Entities:  

Keywords:  Children; Intravenous immunoglobulin; Kawasaki disease; Resistance

Mesh:

Substances:

Year:  2016        PMID: 27491972     DOI: 10.1007/s10067-016-3370-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

1.  Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.

Authors:  Hiromi Muta; Masahiro Ishii; Jun Furui; Yosikazu Nakamura; Toyojiro Matsuishi
Journal:  Acta Paediatr       Date:  2006-02       Impact factor: 2.299

2.  Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease.

Authors:  Pei-pei Fu; Zhong-dong Du; Yue-song Pan
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

3.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

4.  Five years of Kawasaki disease in the Netherlands: a national surveillance study.

Authors:  Carline E Tacke; Willemijn B Breunis; Rob Rodrigues Pereira; Johannes M Breur; Irene M Kuipers; Taco W Kuijpers
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

5.  Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.

Authors:  Satoshi Sato; Hisashi Kawashima; Yasuyo Kashiwagi; Akinori Hoshika
Journal:  Int J Rheum Dis       Date:  2013-04       Impact factor: 2.454

6.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

7.  Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.

Authors:  Donato Rigante; Piero Valentini; Daniela Rizzo; Andrea Leo; Gabriella De Rosa; Roberta Onesimo; Alessia De Nisco; Donatella Francesca Angelone; Adele Compagnone; Angelica Bibiana Delogu
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

8.  Clinical characteristics of Kawasaki syndrome and the risk factors for coronary artery lesions in China.

Authors:  Yu Ruan; Bei Ye; Xiaodong Zhao
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

9.  Epidemiology and risk factors for coronary artery abnormalities in children with complete and incomplete Kawasaki disease during a 10-year period.

Authors:  Georgia Giannouli; Chryssa Tzoumaka-Bakoula; Ioannis Kopsidas; Paraskevi Papadogeorgou; George P Chrousos; Athanasios Michos
Journal:  Pediatr Cardiol       Date:  2013-03-06       Impact factor: 1.655

10.  Kawasaki syndrome and factors associated with coronary artery abnormalities in California.

Authors:  Laura S Callinan; Farzaneh Tabnak; Robert C Holman; Ryan A Maddox; Janice J Kim; Lawrence B Schonberger; Duc J Vugia; Ermias D Belay
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

View more
  21 in total

1.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

2.  Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities.

Authors:  Goshgar Mammadov; Hui Hui Liu; Wei Xia Chen; Guo Zhen Fan; Rui Xue Li; Fei Fei Liu; Sama Samadli; Jing Jing Wang; Yang Fang Wu; Huang Huang Luo; Dong Dong Zhang; Wei Wei; Peng Hu
Journal:  Clin Exp Med       Date:  2019-11-16       Impact factor: 3.984

3.  Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China.

Authors:  Yunjia Tang; Wenhua Yan; Ling Sun; Qiuqin Xu; Yueyue Ding; Haitao Lv
Journal:  Clin Rheumatol       Date:  2018-01-12       Impact factor: 2.980

4.  A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease.

Authors:  Weiguo Qian; Yunjia Tang; Wenhua Yan; Ling Sun; Haitao Lv
Journal:  Ital J Pediatr       Date:  2018-03-09       Impact factor: 2.638

Review 5.  Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.

Authors:  Xuan Li; Ye Chen; Yunjia Tang; Yueyue Ding; Qiuqin Xu; Lin Sun; Weiguo Qian; Guanghui Qian; Liqiang Qin; Haitao Lv
Journal:  Eur J Pediatr       Date:  2018-06-08       Impact factor: 3.183

6.  The role of age-specific N-terminal pro-brain natriuretic peptide cutoff values in predicting intravenous immunoglobulin resistance in Kawasaki disease: a prospective cohort study.

Authors:  Shuran Shao; Chunyan Luo; Kaiyu Zhou; Yimin Hua; Mei Wu; Lei Liu; Xiaoliang Liu; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2019-09-18       Impact factor: 3.054

7.  A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing: a retrospective study on 5277 patients.

Authors:  Xu-Hai Tan; Xiao-Wei Zhang; Xiao-Yun Wang; Xiang-Qian He; Chu Fan; Tie-Wei Lyu; Jie Tian
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

8.  Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study.

Authors:  Shuran Shao; Chunyan Luo; Kaiyu Zhou; Yimin Hua; Mei Wu; Lei Liu; Xiaoliang Liu; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2019-11-27       Impact factor: 3.054

9.  A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old.

Authors:  Shu Wu; Yuan Long; Selena Chen; Yaqian Huang; Ying Liao; Yan Sun; Qingyou Zhang; Chunyu Zhang; Hui Yan; Jianguang Qi; Xueqin Liu; Yonghong Chen; Yong Zhang; Junbao Du
Journal:  Front Pediatr       Date:  2019-12-11       Impact factor: 3.418

10.  Neutropenia Is Not Associated With the Outcomes in Patients With Kawasaki Disease.

Authors:  Yunjia Tang; Miao Gang; Weiguo Qian; Jin Ma; Qiuqin Xu; Haitao Lv
Journal:  Front Pediatr       Date:  2021-06-04       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.